Advantage Investment Management’s AstraZeneca AZN Stock Holding History

Advantage Investment Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$60K	Hold	673	–	–	0.05%	303
2019 Q2	$56K	Hold	673	–	–	0.04%	322
2019 Q1	$54K	Buy	673 +6	+0.9%	+$473	0.04%	329
2018 Q4	$51K	Buy	667 +191	+40%	+$14.9K	0.04%	342
2018 Q3	$38K	Buy	+476	New	+$36K	0.02%	436
2018 Q1	–	Sell	-50	Closed	-$3K	–	1001
2017 Q4	$3K	Hold	50	–	–	﹤0.01%	873
2017 Q3	$3K	Hold	50	–	–	﹤0.01%	883
2017 Q2	$3K	Hold	50	–	–	﹤0.01%	900
2017 Q1	$3K	Hold	50	–	–	﹤0.01%	857
2016 Q4	$3K	Hold	50	–	–	﹤0.01%	798
2016 Q3	$3K	Hold	50	–	–	﹤0.01%	781
2016 Q2	$3K	Sell	50 -317	-86%	-$18.4K	﹤0.01%	745
2016 Q1	$21K	Hold	367	–	–	0.01%	450
2015 Q4	$25K	Buy	367 +317	+634%	+$20.8K	0.01%	434
2015 Q3	$7K	Sell	50 -50	-50%	-$3.29K	﹤0.01%	599
2015 Q2	$7K	Hold	100	–	–	﹤0.01%	639
2015 Q1	$7K	Hold	100	–	–	﹤0.01%	643
2014 Q4	$7K	Buy	+100	New	+$7.16K	0.01%	568

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Advantage Investment Management's AZN Position: Q3 2019 in Review

Advantage Investment Management held its AstraZeneca (AZN) position steady in Q3 2019 at 673 shares worth $60K. The position accounts for 0.05% of the portfolio, ranked #303.

Advantage Investment Management first reported a position in AZN in Q4 2014 and has held it in 18 quarters since. 555 funds tracked by Wall St. Rank hold AZN as of Q3 2019.

Advantage Investment Management held 673 shares of AstraZeneca worth $60K as of Q3 2019.
Advantage Investment Management left its AstraZeneca share count unchanged in Q3 2019.
AstraZeneca made up 0.05% of Advantage Investment Management's portfolio in Q3 2019, its #303 holding.
Advantage Investment Management first reported a position in AstraZeneca in Q4 2014 and has held it in 18 quarters since.
555 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2019.

Based on Advantage Investment Management's 13F filing for Q3 2019, filed 8 Oct 2019.